Posted by Michael Wonder on 18 Dec 2021
FDA approves drug to treat sickle cell disease in patients aged 4 up to 11 years
17 December 2021 - The FDA has granted accelerated approval for Oxbryta (voxelotor) tablets to treat sickle cell disease in paediatric patients aged four up to 11 years.
The FDA had previously granted accelerated approval for Oxbryta for patients aged 12 years and older with sickle cell disease.
